A daughter of Samuel D. Waksal, the chief executive of Imclone systems, sold nearly 1.0 million of company stock a day before the food and Drug Administration rejected Imclone's application to market its cancer drug, according to a filing with the Securities and Exchange Commission.
Daughter of Imclone chief executive sold 1.0 M in stock day before.